Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 2, 2018, Pages 268-278

  Patel, Y A ^a   Gifford, E J ^a   Glass, L M ^a   McNeil, R ^a   Turner, M J ^a   Han, B ^a   Provenzale, D ^a   Choi, S S ^a   Moylan, C A ^a   Hunt, C M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE;

ADULT; ARTICLE; BARIATRIC SURGERY; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DIET THERAPY; DISEASE SEVERITY; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; ETHNICITY; EXERCISE; FEMALE; HEALTH CARE SYSTEM; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VETERANS HEALTH; AGED; BIOPSY; COMPLICATION; DISEASE EXACERBATION; GOVERNMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; UNITED STATES; VETERAN;

ADULT; AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS; VETERANS HEALTH;

EID: 85033476383     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14411     Document Type: Article

References (53)

1. Fryar CD, Herrick K, Afful J, Ogden CL. Cardiovascular disease risk factors among male veterans, U.S., 2009-2012. Am J Prev Med. 2016;50:101-105.
2. Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE. 2017;12:e0173499.
3. Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol 2016;14:301-308.e1-2.
4. Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152:1090-1099.e1.
5. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:124-131.e1.
6. O'Leary TJ, Dominitz JA, Chang KM. Veterans affairs office of research and development: research programs and emerging opportunities in digestive diseases research. Gastroenterology. 2015;149:1652-1661.
7. Kleiner DE, Brunt EM, van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2005;41:1313-1321.
8. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-2273.
9. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654.quiz e39-40.
10. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, MD) 2015;61:1547-1554.
11. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore, MD) 2007;45:846-854.
12. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e10.
13. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology (Baltimore, MD) 2017;65:1557-1565.
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology (Baltimore, MD) 2012;55:2005-2023.
15. Veterans Administration. Veteran Population Projections: FY2010 to FY2040. http://www.va.gov/vetdata/docs/QuickFacts/Population_quickfacts.pdf. Accessed June 14, 2017.
16. US Department of Veterans Affairs. National Center for Veterans Analysis and Statistics. 2015. Washington, DC; DVA. Available at: http://www.va.gov/vetdata
17. Ratziu V, Cadranel JF, Serfaty L, et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012;57:376-383.
18. Youssef NA, Abdelmalek MF, Binks M, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33:1062-1070.
19. Lapham GT, Achtmeyer CE, Williams EC, Hawkins EJ, Kivlahan DR, Bradley KA. Increased documented brief alcohol interventions with a performance measure and electronic decision support. Med Care. 2012;50:179-187.
20. Using AUDIT-C Alcohol Screening Data in VA Research: Interpretation, Strengths, Limitations, & Sources. Available at: http://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/vci-031511.pdf In January 2015.
21. Vuppalanchi R, Unalp A, van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481-486.
22. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155.
23. Bazick J, Donithan M, Neuschwander-Tetri BA, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015;38:1347-1355.
24. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740-751.
25. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
26. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723-730.
27. Damschroder L. Diabetes Prevention Program (DPP) Translation in VA Health Services Research & Development. Available at: https://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/video_archive.cfm?SessionID=1266 January 5, 2017.
28. Maciejewski ML, Arterburn DE, van Scoyoc L, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151:1046-1055.
29. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379-388; quiz e15-6.
30. Leventhal H, Leventhal EA, Breland JY. Cognitive science speaks to the “common-sense” of chronic illness management. Ann Behav Med. 2011;41:152-163.
31. Rodriguez V, Andrade AD, Garcia-Retamero R, et al. Health literacy, numeracy, and graphical literacy among veterans in primary care and their effect on shared decision making and trust in physicians. J Health Commun. 2013;18:273-289.
32. Fisher EB, Coufal MM, Parada H, et al. Peer support in health care and prevention: cultural, organizational, and dissemination issues. Ann Rev Public Health. 2014;35:363-383.
33. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (Baltimore, MD) 2010;51:1820-1832.
34. Hassan MM, Kaseb A, Etzel CJ, et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013;52:E139-E147.
35. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2011;53:1883-1894.
36. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465.
37. Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic fatty liver disease in Latinos. Clin Gastroenterol Hepatol 2016;14:5-12; quiz e9-10.
38. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, MD) 1999;30:1356-1362.
39. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224-1229.e1-2.
40. Bambha K, Belt P, Abraham M, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2012;55:769-780.
41. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:753-759.
42. Wu P, Hua Y, Tan S, Li M, Yongxiang S, Fang G. Interactions of smoking with rs833061 polymorphism on the risk of non-alcoholic fat liver disease in Hubei Han population: a preliminary case-control study. Iran J Basic Med Sci. 2015;18:1112-1117.
43. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-530.e1; quiz e60.
44. Shen H, Peng JL, Tayarachakul S, Liangpunsakul S. Association between serum cotinine level and prevalence of non-alcoholic fatty liver disease: a cross-sectional study from the Third national health and nutrition examination survey. J Investig Med. 2017;65:43-48.
45. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2014;60:565-575.
46. Cui J, Ang B, Haufe W, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015;41:1271-1280.
47. Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol. 2015;110:1298-1304.
48. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377:756-768.
49. Husain N, Blais P, Kramer J, et al. Nonalcoholic fatty liver disease (NAFLD) in the Veterans administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014;40:949-954.
50. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology (Baltimore, MD) 2016;64:405-414.
51. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England) 2016;387:679-690.
52. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2010;52:913-924.
53. Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: how successful is it in the real world? Clin Mol Hepatol. 2017.23:239-248.